drugset
drugset / Trial / NCT00087867

Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma

NCT00087867 ↗

Phase 2 Completed 62 enrolled Scios, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The main objective of this study is to assess the efficacy of SCIOS-469 as monotherapy in relapsed, refractory patients with multiple myeloma (MM), based on response rates.

Timeline

Start
2004-06
Primary completion
—
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject TALMAPIMOD Small molecule 60 mg Oral
Background Bortezomib Small molecule 1 mg/m2 Intravenous

Indications

plasma cell myeloma